Monte Rosa Therapeutic
Logotype for Monte Rosa Therapeutic Inc

Monte Rosa Therapeutic (GLUE) investor relations material

Monte Rosa Therapeutic Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Monte Rosa Therapeutic Inc
Jefferies Global Healthcare Conference summary17 Nov, 2026

Molecular glue platform

  • True small-molecule degraders bind ubiquitin ligases and reshape their surface to create a new protein-protein interaction, enabling selective protein removal; selectivity is intended to support safety.

  • The approach is being applied across multiple disease areas.

MRT-8102 and indication strategy

  • MRT-8102 targets the NLRP3 inflammasome in sterile inflammation linked to intrinsic metabolites; prioritized indications are gout, ASCVD and hidradenitis suppurativa (HS).

  • Gout was viewed as potentially the lowest-risk indication, supported by clinical and preclinical validation; ASCVD remains a focus despite the ZEUS trial outcome, while HS carries risk from placebo overperformance in the field.

  • Management attributed ZEUS limitations to IL-6 inhibition leaving ~20%-25% of IL-6 active and trial-design issues, including comorbidities; the ASCVD program will target the pathway further upstream and use a different design.

Gout phase II

  • GEMINI-1 is a small, two-dose study with an open-label expansion; frequent-flare patients start therapy during an acute flare, with prevention of subsequent flares as the key outcome.

  • The trial was on track to initiate in Q4 2026, with a data readout guided for H2 2027; management expressed confidence in timely recruitment.

  • Historical untreated flare rates are 50%-60% over 3-6 months; cutting that rate in half was described as a meaningful benchmark, subject to the recruited population and its characteristics.

  • The study will not use placebo control; historical data and prior IL-1β antibody results were cited as context for interpreting flare reduction.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Monte Rosa Therapeutic earnings date

Logotype for Monte Rosa Therapeutic Inc
38th Annual Healthcare Conference1 Dec, 2026
Monte Rosa Therapeutic
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Monte Rosa Therapeutic earnings date

Logotype for Monte Rosa Therapeutic Inc
38th Annual Healthcare Conference1 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Monte Rosa Therapeutics Inc. is a clinical-stage biotechnology company focused on developing molecular glue degraders (MGDs). These small molecules are designed to selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation processes. The company targets a range of therapeutic areas, including oncology, autoimmune, and inflammatory diseases. Monte Rosa utilizes its proprietary QuEEN platform, which integrates proteomics, structural biology, AI, and machine learning, to rapidly identify and develop highly selective protein degraders. The company operates out of Boston, Massachusetts, with additional research facilities in Basel, Switzerland. Its shares trade on the NASDAQ.